"The U.S. Food and Drug Administration today granted accelerated approval to Perjeta (pertuzumab) as part of a complete treatment regimen for patients with early stage breast cancer before surgery (neoadjuvant setting). Perjeta is the first FDA-ap"...
- Advise pregnant women and females of reproductive potential that PERJETA exposure can result in fetal harm, including embryo-fetal death or birth defects [see WARNINGS AND PRECAUTIONS and Use in Specific Populations]
- Advise females of reproductive potential to use effective contraception while receiving PERJETA and for 6 months following the last dose of PERJETA [see WARNINGS AND PRECAUTIONS and Use in Special Populations]
- Advise nursing mothers treated with PERJETA to discontinue nursing or discontinue PERJETA, taking into account the importance of the drug to the mother [see Use in Specific Populations].
- Encourage women who are exposed to PERJETA during pregnancy to enroll in the MotHER Pregnancy Registry by contacting 1-800-690-6720 [see WARNINGS AND PRECAUTIONS and Use in Specific Populations]
Last reviewed on RxList: 4/7/2015
This monograph has been modified to include the generic and brand name in many instances.
Additional Perjeta Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find support and advances in treatment.